semaglutide and cardiovascular Outcomes in Patients with Type 2 Diabetes Oral Semaglutide Improves Cardiovascular Risk

It works by simultaneously activating three incretin-related receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

The ongoing CONFIDENCE trial (NCT05254002) is an international randomised controlled double-blind trial that will directly assess the effects of finerenone plus empagliflozin on albuminuria and characterise the efficacy and safety of this drug combination in the setting of type 2 diabetes

Maintenance of lost weight and long-term management of obesity

The plaintiffs vision loss has not only caused severe physical injury but has also produced significant emotional harm and forced radical changes to his daily life

In tropical and sub-tropical regions